Company Overview

Alembic Pharmaceuticals Limited submitted its comprehensive Annual Report for FY26, reporting strong financial performance with revenue growth of 10% to ₹7,345 crore and net profit increase of 16% to ₹675 crore. The company maintained robust operational metrics with EBITDA growing 12% to ₹1,177 crore and net cash flow from operations surging 790% to ₹783 crore.

Financial Performance

Standalone revenue reached ₹6,651.38 crores (10.3% growth) with net profit increasing 27.3% to ₹640.42 crores. Key financial ratios showed improvement with current ratio at 1.75 (3% improvement), return on equity at 12.43% (7% improvement), and net profit ratio at 9.19% (5% improvement). The Board recommended a final dividend of ₹12 per equity share (600%), increased from ₹11 (550%) in the previous year.

Business Segment Performance

India Branded Business delivered ₹2,458 crore revenue (5% growth) with focus on specialty therapies in Gynaecology and Ophthalmology. International Generics Business showed strong performance with U.S. Generics growing 13% despite pricing pressure and 15 new product launches, while RoW Generics grew 20% with 94 product filings. API business achieved 15% volume growth with captive consumption exceeding 50% of formulation requirements.

Strategic Developments

The company strategically pivoted toward complex generics and branded specialty markets, marked by the acquisition of Utility Therapeutics Ltd and successful launch of Pivya (pivmecillinam) under Alembic Therapeutics in the U.S. women's health segment. Manufacturing operations expanded with 10 facilities (9 USFDA-approved), including the commissioned Pithampur facility for better distribution reach. R&D investment remained high at ₹712 crore (10% of revenue) focused on complex injectables, peptides, and drug-device combinations.

Sustainability & Compliance

Alembic achieved significant environmental milestones with 95% water neutrality through recharge wells, 58.8% renewable energy usage (targeting 90%), and SBTi-approved emissions reduction targets (63% reduction by FY34). Bureau Veritas provided reasonable assurance on BRSR Core parameters covering GHG emissions, water consumption, and waste management. All USFDA inspected facilities have Establishment Inspection Reports, with successful completion of multiple regulatory audits.

Corporate Governance & AGM

The 16th Annual General Meeting is scheduled for 5th August 2026 to approve dividend declaration, reappointment of Mr. Pranav Amin, and appointment of Mr. Sujit Jaysukh Bhayani as Independent Director. The Board comprises 3 Promoter Executive Directors, 1 Non-Executive Non-Independent Director, and 4 Independent Directors, with no material weaknesses in internal financial controls observed.

Risk Management & Outlook

The company disclosed exposure to financial risks including credit, liquidity, and market risks, with sensitivity analysis showing ₹57.07 crore impact from 5% currency fluctuation. Net debt stood at ₹1,164 crore (1x EBITDA) with strong credit ratings (CRISIL A1+/AA+). Outlook expects India business to move closer to market growth, international generics to grow low-to-mid teens, and maintained margin protection through better utilization and cost discipline.